Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 18/20 | 0.59 |
| ▸ | EGLN2 | Q96KS0 | 3/20 | 0.59 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.43 |
| ▸ | EGLN3 | Q9H6Z9 | 2/20 | 0.43 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.41 |
| ▸ | THRA | P10827 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL522924 | 0.86 | EGLN1 (0.77) | EGLN1EGLN2FTOBBOX1 | |
| SCHEMBL30274444 | 0.86 | EGLN1 (0.77) | EGLN1EGLN2FTOBBOX1 | |
| SCHEMBL6060578 | 0.82 | EGLN2 (0.52) | EGLN1EGLN2 | |
| SCHEMBL2356670 | 0.82 | EGLN1 (0.50) | EGLN1EGLN2FTOEGLN3BBOX1 | |
| SCHEMBL1115849 | 0.81 | EGLN1 (0.77) | EGLN1EGLN2FTOBBOX1THRA | |
| SCHEMBL522835 | 0.81 | EGLN1 (0.66) | EGLN1EGLN2FTOEGLN3BBOX1 | |
| SCHEMBL15549510 | 0.81 | EGLN1 (0.75) | EGLN1EGLN2FTOBBOX1THRA | |
| Water SCHEMBL15548472 | 0.81 | EGLN1 (0.75) | EGLN1EGLN2FTOBBOX1THRA | |
| SCHEMBL15549041 | 0.81 | EGLN1 (0.75) | EGLN1EGLN2FTOBBOX1THRA | |
| SCHEMBL522832 | 0.78 | EGLN1 (0.64) | EGLN1EGLN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1893186-A2 | IMPROVED TREATMENT FOR ANEMIA USING A HIF-ALPHA STABILISING AGENT | FIBROGEN, INC. (US) | 2008-03-05 | — | — | EP | claimed |
| WO-2006133391-A2 | IMPROVED TREATMENT FOR ANEMIA USING A HIF-ALPHA STABILISING AGENT | FIBROGEN, INC. (US) | 2006-12-14 | — | — | WO | claimed |
| EP-1644336-A1 | NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND THEIR USE IN INCREASING ENDOGENEOUS ERYTHROPOIETIN | FIBROGEN, INC. (US) | 2006-04-12 | — | — | EP | claimed |
| WO-2004108681-A1 | NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND THEIR USE IN INCREASING ENDOGENOUS ERYTHROPOIETIN | FIBROGEN, INC. (US) | 2004-12-16 | — | — | WO | claimed |
| EP-2035000-A1 | HIF HYDROXYLASE INHIBITORS FOR TREATMENT OF ANEMIA OF CANCER | FIBROGEN, INC. (US) | 2009-03-18 | — | — | EP | disclosed |
| EP-1991269-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF STROKE | FIBROGEN, INC. (US) | 2008-11-19 | — | — | EP | disclosed |
| WO-2007146438-A1 | HIF HYDROXYLASE INHIBITORS FOR TREATMENT OF ANEMIA OF CANCER | FIBROGEN, INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007097929-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF STROKE | FIBROGEN, INC. (US) | 2007-08-30 | — | — | WO | disclosed |
| EP-1644336-A1 | NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND THEIR USE IN INCREASING ENDOGENEOUS ERYTHROPOIETIN | FIBROGEN, INC. (US) | 2006-04-12 | — | — | EP | disclosed |
| WO-2004108681-A1 | NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND THEIR USE IN INCREASING ENDOGENOUS ERYTHROPOIETIN | FIBROGEN, INC. (US) | 2004-12-16 | — | — | WO | disclosed |